Wat kan Small Molecule Modelling u bieden?
How have computational protocols advanced in the last few years to make quantifiable impact in projects for small molecules in drug design?
Join us, for a 1-hour seminar and we will share a birds-eye view of how state-of-the-art science is being used routinely to alleviate challenging design questions and enabling ideation across different teams. This is with a view to achieving one critical goal: speeding up drug discovery cycles.
Join this webinar to learn about:
About Schrödinger:
Schrödinger is a provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The company is also applying its computational platform to a robust pipeline of drug discovery programs in collaboration with pharmaceutical companies and has co-founded leading biotech companies.
In addition, the company is using its platform to advance a pipeline of internal, wholly-owned drug discovery programs.
More information at www.schrodinger.com
Join us, for a 1-hour seminar and we will share a birds-eye view of how state-of-the-art science is being used routinely to alleviate challenging design questions and enabling ideation across different teams. This is with a view to achieving one critical goal: speeding up drug discovery cycles.
Join this webinar to learn about:
- Modelling concepts
- How modelling can be useful to small molecule drug design
- A typical drug design casestudy using Schrodinger Modelling and how it benefits project progression
- How you might want to be involved with Schrodinger for your projects
About Schrödinger:
Schrödinger is a provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The company is also applying its computational platform to a robust pipeline of drug discovery programs in collaboration with pharmaceutical companies and has co-founded leading biotech companies.
In addition, the company is using its platform to advance a pipeline of internal, wholly-owned drug discovery programs.
More information at www.schrodinger.com